- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- 蛋白實(shí)驗(yàn)
- Protein A/G免疫沉淀磁珠
- Anti-DYKDDDDK Tag免疫磁珠
- Anti-DYKDDDDK Tag親和凝膠
- Anti-Myc免疫磁珠
- Anti-HA免疫磁珠
- 磁力架
- Poly DYKDDDDK Tag多肽
- 蛋白酶抑制劑Cocktail
- 蛋白酶抑制劑Cocktail(DMSO儲液)
- 磷酸酶抑制劑Cocktail
- 細(xì)胞實(shí)驗(yàn)
- Cell Counting Kit-8 (CCK-8)
- 新產(chǎn)品
- 聯(lián)系我們
LCL161
LCL-161, 一種second mitochondrial activator of caspase (SMAC, 線粒體促凋亡蛋白)模擬物, 能有效地結(jié)合并抑制多種IAPs(i.e. XIAP, c-IAP)。
LCL161 Chemical Structure
CAS: 1005342-46-0
產(chǎn)品質(zhì)控
批次：
純度：
99.99%
99.99
LCL161相關(guān)產(chǎn)品
| 相關(guān)靶點(diǎn) | cIAP XIAP | 點(diǎn)擊展開 |
|---|---|---|
| 相關(guān)產(chǎn)品 | Birinapant BV-6 Xevinapant (AT406) GDC-0152 AZD5582 SM-164 SM-164 Tolinapant (ASTX660) | 點(diǎn)擊展開 |
| 相關(guān)化合物庫 | 自噬化合物庫 凋亡分子化合物庫 鐵死亡化合物庫 細(xì)胞焦亡化合物庫 線粒體靶向化合物庫 | 點(diǎn)擊展開 |
相關(guān)信號通路圖
細(xì)胞實(shí)驗(yàn)數(shù)據(jù)示例
| 細(xì)胞系 | 實(shí)驗(yàn)類型 | 給藥濃度 | 孵育時(shí)間 | 活性描述 | 文獻(xiàn)信息 |
|---|---|---|---|---|---|
| LOX | Function assay | 100 mg/kg | 8 hrs | Plasma concentration in nude mouse xenografted with human LOX cells at 100 mg/kg, po measured at 8 hrs, Cp = 3.3 μM. | 24093940 |
| H460 | Function assay | 3.3 uM | 5 days | Potentiation of conatumumab-induced cytotoxicity against human H460 cells at 3.3 uM after 5 days by MTS assay | 24083782 |
| LS180 | Function assay | 3.3 uM | 5 days | Potentiation of conatumumab-induced cytotoxicity against human LS180 cells at 3.3 uM after 5 days by MTS assay | 24083782 |
| LOX | Function assay | 3.3 uM | 3 days | Potentiation of conatumumab-induced cytotoxicity against human LOX cells at 3.3 uM after 3 days by MTS assay | 24083782 |
| SW620 | Function assay | 3.3 uM | 5 days | Potentiation of conatumumab-induced cytotoxicity against human SW620 cells at 3.3 uM after 5 days by MTS assay | 24083782 |
| SW620 | Function assay | 1.1 uM | 5 days | Potentiation of conatumumab-induced cytotoxicity against human SW620 cells at 1.1 uM after 5 days by MTS assay | 24083782 |
| HCT15 | Function assay | 3.3 uM | 5 days | Potentiation of conatumumab-induced cytotoxicity against human HCT15 cells at 3.3 uM after 5 days by MTS assay | 24083782 |
| BxPC3 | Function assay | 3.3 uM | 5 days | Potentiation of conatumumab-induced cytotoxicity against human BxPC3 cells at 3.3 uM after 5 days by MTS assay | 24083782 |
| MDA-MB-231 | Function assay | 2.5 to 10 uM | 19 hrs | Binding affinity to cIAP1 BIR3 domain in human MDA-MB-231 cells assessed as increase in TNFalpha level at 2.5 to 10 uM after 19 hrs by ELISA | 24083782 |
| LOX | Function assay | 100 mg/kg | 8 hrs | Potentiation of conatumumab-induced cIAP1 degradation in human LOX cells xenografted in mouse at 100 mg/kg, po after 8 hrs by Western blotting analysis | 24083782 |
| LOX | Function assay | 100 mg/kg | 8 hrs | Drug uptake in tumor of nude mouse xenografted with human LOX cells at 100 mg/kg, po measured at 8 hrs, Drug uptake = 18.4 μM. | 24093940 |
| SW620 | Function assay | 2.5 uM | 5 days | Induction of sensitization of human SW620 cells to conatumumab-induced apoptosis assessed as cell viability at 2.5 uM after 5 days by MTS assay | 24093940 |
| LOX | Function assay | 100 mg/kg | 8 hrs | In vivo inhibition of XIAP BIR2 domain in human LOX cells xenografted in nude mouse assessed as potentiation of conatumumab-induced caspase 3/7 activity at 100 mg/kg, po after 8 hrs by Western blot analysis | 24093940 |
| LOX | Function assay | 100 mg/kg | 8 hrs | In vivo inhibition of XIAP BIR2 domain in human LOX cells xenografted in nude mouse assessed as increase in caspase 3/7 activity at 100 mg/kg, po after 8 hrs by Western blot analysis | 24093940 |
| MDA-MB-231 | Function assay | 0.37 to 3.3 uM | 19 hrs | Inhibition of cIAP1/2 in human MDA-MB-231 cells assessed as induction of TNFalpha level at 0.37 to 3.3 uM after 19 hrs by ELISA | 24093940 |
| CHL1 | Function assay | 0.4 to 10 uM | 28 hrs | Inhibition of cIAP1 in human CHL1 cells at 0.4 to 10 uM after 28 hrs by Western blot analysis | 24093940 |
| SKMES1 | Function assay | 2.5 uM | 5 days | Potentiation of conatumumab-induced apoptosis in human SKMES1 cells at 2.5 uM after 5 days by MTS assay | 24093940 |
| Capan1 | Function assay | 2.5 uM | 5 days | Potentiation of conatumumab-induced apoptosis in human Capan1 cells at 2.5 uM after 5 days by MTS assay | 24093940 |
| AGS | Function assay | 2.5 uM | 5 days | Induction of sensitization of human AGS cells to conatumumab-induced apoptosis assessed as cell viability at 2.5 uM after 5 days by MTS assay | 24093940 |
| U118MG | Function assay | 2.5 uM | 5 days | Potentiation of conatumumab-induced apoptosis in human U118MG cells at 2.5 uM after 5 days by MTS assay | 24093940 |
| PC3 | Function assay | 2.5 uM | 5 days | Induction of sensitization of human PC3 cells to conatumumab-induced apoptosis assessed as cell viability at 2.5 uM after 5 days by MTS assay | 24093940 |
| MDA-MB-231 | Antitumor assay | 30 mg/kg | 24 days | Antitumor activity against human MDA-MB-231 cells xenografted in Balb/c SCID mouse assessed as tumor growth inhibition at 30 mg/kg administered via oral gavage for 24 days | 28492317 |
| A549 | Function assay | 1 uM | 3 hrs | Induction of cIAP2 degradation in human A549 cells assessed as reduction in cIAP2 protein level at 1 uM incubated for 3 hrs by Western blot analysis | 31550155 |
| SK-MEL-28 | Function assay | 1 uM | 3 hrs | Induction of cIAP1 degradation in human SK-MEL-28 cells assessed as reduction in cIAP1 protein level at 1 uM incubated for 3 hrs by Western blot analysis | 31550155 |
| SK-MEL-28 | Function assay | 1 uM | 3 hrs | Induction of cIAP2 degradation in human SK-MEL-28 cells assessed as reduction in cIAP2 protein level at 1 uM incubated for 3 hrs by Western blot analysis | 31550155 |
| HEK293T | Function assay | 10 uM | 6 hrs | Covalent binding affinity to HA-BIR3 domain of XIAP (unknown origin) expressed in HEK293T cells assessed as increase in band intensity at 10 uM incubated for 6 hrs by Western blot analysis | 31550155 |
| A549 | Function assay | 1 uM | 3 hrs | Induction of cIAP1 degradation in human A549 cells assessed as reduction in cIAP1 protein level at 1 uM incubated for 3 hrs by Western blot analysis | 31550155 |
| LOX | Function assay | 8 hrs | Potentiation of conatumumab-induced caspase 3/7 activation in human LOX cells xenografted in mouse after 8 hrs by fluorescence assay | 24083782 | |
| SW620 | Function assay | 5 days | Induction of sensitization of human SW620 cells to conatumumab-induced apoptosis assessed as cell viability after 5 days by MTS assay, EC90 = 6.66 μM. | 24093940 | |
| MDA-MB-231 | Function assay | 2 hrs | Induction of cIAP1 degradation in human MDA-MB-231 cells after 2 hrs, EC50 = 0.0004 μM. | 28492317 | |
| MDA-MB-231 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell proliferation after 72 hrs by alamar blue assay, EC50 = 0.0078 μM. | 28492317 | |
| HEK293 | Function assay | 2 hrs | Inhibition of full length FLAG-tagged XIAP (unknown origin) interaction with full length untagged caspase-9 expressed in HEK293 cells after 2 hrs by immunoprecipitation assay, EC50 = 0.035 μM. | 28492317 | |
| MDA-MB-231 | Function assay | 2 hrs | Induction of intracellular cIAP1 degradation in human MDA-MB-231 cells after 2 hrs, IC50 = 0.0004 μM. | 30091600 | |
| MDA-MB-231 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by Alamar blue assay, IC50 = 0.0078 μM. | 30091600 | |
| HEK293 | Function assay | 2 hrs | Inhibition of full length FLAG-tagged XIAP (unknown origin) interaction with full length untagged caspase-9 expressed in HEK293 cells after 2 hrs by immunoprecipitation assay, IC50 = 0.035 μM. | 30091600 | |
| SKOV3 | Apoptosis assay | 48 hrs | Induction of apoptosis in human SKOV3 cells assessed caspase-3 activation after 48 hrs by IncuCyte S3 live-cell analysis, EC50 = 0.001 μM. | 31095386 | |
| SKOV3 | Apoptosis assay | 24 hrs | Induction of apoptosis in human SKOV3 cells assessed caspase-3 activation after 24 hrs by IncuCyte S3 live-cell analysis, EC50 = 0.003 μM. | 31095386 | |
| BL21(DE3) | Function assay | 2 hrs | Displacement of biotinylated AVPF from N-terminal His tagged recombinant human XIAP-BIR3 domain (253 to 347 residues) expressed in Escherichia coli BL21(DE3) cells incubated for 2 hrs by DELFIA, IC50 = 0.048 μM. | 31095386 | |
| BL21(DE3) | Function assay | 8 hrs | Displacement of biotinylated AVPF from N-terminal His tagged recombinant human XIAP-BIR3 domain (253 to 347 residues) expressed in Escherichia coli BL21(DE3) cells incubated for 8 hrs by DELFIA, IC50 = 0.053 μM. | 31095386 | |
| CCRF-CEM | Antiproliferative assay | Antiproliferative activity against human CCRF-CEM cells, GI50 = 0.25 μM. | 28435526 | ||
| 點(diǎn)擊查看更多細(xì)胞系數(shù)據(jù) | |||||
生物活性
| 產(chǎn)品描述 | LCL-161, 一種second mitochondrial activator of caspase (SMAC, 線粒體促凋亡蛋白)模擬物, 能有效地結(jié)合并抑制多種IAPs(i.e. XIAP, c-IAP)。 | ||
|---|---|---|---|
| 靶點(diǎn) |
|
| 體外研究(In Vitro) | ||||
| 體外研究活性 | LCL161以高親和力與凋亡抑制蛋白因子(IAPs)結(jié)合，并啟動對cIAP1和cIAP2的破壞，其通過胱天蛋白酶的激活進(jìn)一步誘導(dǎo)細(xì)胞凋亡。LCL161單獨(dú)給藥時(shí)適度抑制表達(dá)FLT3-ITD的細(xì)胞生長，IC50的范圍為~0.5 μM (Ba/F3-FLT3-ITD 細(xì)胞)到~4 μM (MOLM13-luc+ 細(xì)胞)。觀察到的LCL161抗D835Y突變體的效力相當(dāng)高，測試抗Ba/F3-D835Y細(xì)胞時(shí)，IC50為~50 nM。LCL161 與PKC412結(jié)合治療MOLM13-luc+細(xì)胞比其任何一個(gè)藥劑單獨(dú)使用具有更顯著的細(xì)胞殺傷力，Calcusyn復(fù)合指數(shù)表明其具有協(xié)同作用。 PKC412和LCL161誘導(dǎo)MOLM13-luc+細(xì)胞的凋亡。PKC412 和 LCL161結(jié)合比其單獨(dú)使用能夠?qū)е赂叩募?xì)胞凋亡率。LCL161通過與PKC412陽性結(jié)合，抑制基質(zhì)介導(dǎo)的表達(dá)FLT3的突變細(xì)胞的存活。LCL161抑制Ba/F3.p210細(xì)胞的生長，IC50為~100 nM。LCL161與ABL抑制劑，伊馬替尼結(jié)合，能夠協(xié)同抗BCR-ABL表達(dá)的細(xì)胞。對于在靶蛋白表達(dá)點(diǎn)突變的耐藥細(xì)胞，LCL161也具有抵抗活性。1000 nM的LCL161能夠大部分或完全殺死耐PKC412的Ba/F3衍生的細(xì)胞系，其在FLT3的ATP結(jié)合囊表達(dá)含有點(diǎn)突變的FLT3-ITD。100到1000 nM濃度的LCL161也表現(xiàn)出抗Ba/F3細(xì)胞的活性， Ba/F3細(xì)胞能夠表達(dá)各種伊馬替尼和尼羅替尼耐藥的BCR-ABL點(diǎn)突變。[1] 對LCL161抗23細(xì)胞系的評估，通過兒科臨床前測試計(jì)劃(PPTP)在體外進(jìn)行96小時(shí)。對23種測試PPTP細(xì)胞系中的其中3種，10 μM濃度下的LCL161能夠抑制50%的生長。3種細(xì)胞系包括2種T細(xì)胞ALL細(xì)胞系(COG-LL-317和CCRF-CEM)，以及間變性大細(xì)胞淋巴瘤細(xì)胞系(Karpas-299)，CCRF-CEM和Karpas-299表現(xiàn)出較低的相對IC50值(分別為0.25和1.6 μM)。[2] LCL161對人體免疫亞群表現(xiàn)出免疫調(diào)節(jié)性能。用LCL161處理T淋巴細(xì)胞顯著增強(qiáng)具有激活作用的細(xì)胞因子分泌，對 CD4和CD8 T細(xì)胞生存或分化的作用很小。LCL161處理外周血單核細(xì)胞，在體外合成多肽存在下，顯著增強(qiáng)初始T細(xì)胞的啟動。髓樣樹突狀細(xì)胞在LCL161作用下表型成熟，表明降低了基于腫瘤抗原對抗疫苗的能力。這些作用可能通過觀察到的典型和非典型NF-κB途徑的激活介導(dǎo)，伴隨LCL161導(dǎo)致抗凋亡分子上調(diào)。[3] |
|||
|---|---|---|---|---|
| 細(xì)胞實(shí)驗(yàn) | 細(xì)胞系 | 人 T 細(xì)胞 ALL 細(xì)胞系 COG-LL-317 | ||
| 濃度 | ~10 μM | |||
| 孵育時(shí)間 | 96小時(shí) | |||
| 方法 | 使用DIMSCAN進(jìn)行體外測試 |
|||
| 實(shí)驗(yàn)圖片 | 檢測方法 | 檢測指標(biāo) | 實(shí)驗(yàn)圖片 | PMID |
| Western blot | cIAP1 / cIAP2 / XIAP / surivivin |
|
27737687 | |
| Growth inhibition assay | Cell viability |
|
27737687 | |
| 體內(nèi)研究(In Vivo) | ||
| 體內(nèi)研究活性 | LCL161顯著增強(qiáng)PKC412抑制Ba/F3-FLT3-ITD-luc+細(xì)胞體內(nèi)生長的能力。LCL161能夠與標(biāo)準(zhǔn)化療劑，阿糖胞苷和阿霉素陽性結(jié)合，抗FLT3-ITD表達(dá)細(xì)胞和D835Y表達(dá)細(xì)胞。與LCL161結(jié)合能夠?qū)崿F(xiàn)抑制白血病生長的累加作用。LCL161 (100 毫克/千克)增強(qiáng)高適度劑量對患有白血病小鼠的體內(nèi)作用。[1] 通過兒科臨床前測試程序(PPTP)測試CL161(口服給藥，一周兩次)在體內(nèi)(30 或 75 毫克/千克[實(shí)體瘤] 或100 毫克/千克 [ALL])的作用。LCL161誘導(dǎo)顯著的EFS在大約三分之一實(shí)體瘤異種移植物(osteosarcoma and glioblastoma) 中的分布差異，但不影響ALL異種移植物中的情況。沒有觀察到可評價(jià)客觀療效者。在體內(nèi)，LCL161對兒科臨床前模型研究表現(xiàn)出有限的單劑量活性。[2] |
|
|---|---|---|
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03111992 | Completed | Multiple Myeloma |
Novartis Pharmaceuticals|Novartis |
December 18 2017 | Phase 1 |
| NCT01934634 | Unknown status | Metastatic Pancreatic Cancer |
US Oncology Research|Novartis Pharmaceuticals|Delta Clinical Research LLC |
March 2014 | Phase 1 |
| NCT01968915 | Completed | Neoplasms |
Novartis Pharmaceuticals|Novartis |
November 2013 | Phase 1 |
| NCT01617668 | Completed | Breast Cancer |
Novartis Pharmaceuticals|Novartis |
August 2012 | Phase 2 |
化學(xué)信息&溶解度
| 分子量 | 500.63 | 分子式 | C26H33FN4O3S |
| CAS號 | 1005342-46-0 | SDF | Download LCL161 SDF |
| Smiles | CC(C(=O)NC(C1CCCCC1)C(=O)N2CCCC2C3=NC(=CS3)C(=O)C4=CC=C(C=C4)F)NC | ||
| 儲存條件(自收到貨起) | |||
|
體外溶解度 |
DMSO : 100 mg/mL ( (199.74 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO) Ethanol : 100 mg/mL (199.74 mM) Water : Insoluble |
摩爾濃度計(jì)算器 |
|
體內(nèi)溶解度 現(xiàn)配現(xiàn)用，請按從左到右的順序依次添加，澄清后再加入下一溶劑 |
動物體內(nèi)配方計(jì)算器 | ||||
實(shí)驗(yàn)計(jì)算
摩爾濃度計(jì)算器
動物體內(nèi)配方計(jì)算器（澄清溶液）
第一步：請輸入基本實(shí)驗(yàn)信息（考慮到實(shí)驗(yàn)過程中的損耗，建議多配一只動物的藥量）
mg/kg
g
μL
只
第二步：請輸入動物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請聯(lián)系Selleck為您提供正確的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
計(jì)算結(jié)果：
工作液濃度： mg/ml；
DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請先聯(lián)系Selleck）；
體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH2O，混勻澄清。
體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。
注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進(jìn)行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。
技術(shù)支持
在訂購、運(yùn)輸、儲存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱tech@selleck.cn，直接聯(lián)系到我們。我們會在24小時(shí)內(nèi)盡快聯(lián)系您。
如果有其他問題，請給我們留言。
* 必填項(xiàng)
Tags: buy LCL161 | LCL161 supplier | purchase LCL161 | LCL161 cost | LCL161 manufacturer | order LCL161 | LCL161 distributor
